查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2111104

神經認知生物標記解決方案市場預測至2034年—按生物標記類型、技術、適應症、樣本類型、最終用戶和地區分類的全球分析

Neurocognitive Biomarker Solutions Market Forecasts to 2034 - Global Analysis By Biomarker Type, Technology, Clinical Indication, Sample Type, End User, and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球神經認知生物標記解決方案市場預計將在 2026 年達到 52 億美元，並在預測期內以 18.2% 的複合年成長率成長，到 2034 年達到 198 億美元。

神經認知生物標記解決方案是識別、測量和分析與認知功能、神經系統疾病和腦部健康相關的生物學和數位指標的先進技術。這些解決方案結合了神經影像學、血液生物標記、電生理測量、穿戴式感測器、人工智慧和數位認知功能評估，以支持早期診斷、疾病監測、治療方案選擇和個人化醫療。神經認知生物標記解決方案廣泛應用於臨床研究、醫院、藥物研發和精準醫療領域。神經系統疾病盛行率的不斷上升以及對基於生物標記的診斷技術投資的持續成長，正在推動神經認知生物標記解決方案在全球範圍內的普及應用。

神經系統疾病盛行率上升

在全球範圍內，泛自閉症障礙、注意力不足過動症（ADHD）和發育遲緩等神經系統疾病的盛行率持續上升。這一趨勢推動了對人工智慧（AI）驅動的篩檢工具的需求，這些工具能夠實現早期發現和早期療育。各公司正投資研發先進演算法，以提高診斷準確性並減少對傳統方法的依賴。各國政府正透過醫療保健資金和政策框架支持神經發育相關措施。家庭和看護者越來越希望找到便捷且非侵入性的兒童和成人篩檢方法。機器學習技術的進步和多模態資料的整合正在提升預測能力。所有這些因素共同推動了人工智慧驅動的神經發育篩檢的廣泛應用。

複雜的生物標記檢驗過程

生物標記檢驗需要大規模臨床試驗和法規核准，這延緩了商業化。企業在開發臨床可靠的生物標記方面面臨高昂的成本和漫長的週期。與擁有先進研發能力的大型競爭對手相比，小規模公司在檢驗舉步維艱。法律規範要求在批准前提供嚴格的證據，這進一步加劇了問題的複雜性。消費者對人工智慧驅動的篩檢的信心取決於經過驗證且準確性得到證實的生物標記。跨區域標準化方案的需求也進一步增加了推廣應用的難度。因此，生物標記檢驗仍然是市場快速成長的一大障礙。

血液生物標記創新

基於血液的生物標記為非侵入性神經發育篩檢提供了一條充滿希望​​的途徑。該領域的創新為將人工智慧驅動的診斷擴展到影像學以外的領域提供了契機。對於企業而言，這帶來了許多益處，例如提高可及性並減少對高成本神經影像技術的依賴。世界各國政府正將生物標記研究納入其精準醫療策略。家庭對便捷可靠的篩檢方法的需求日益成長，推動了對基於血液的解決方案的投資。人工智慧整合技術的進步正在提高生物標記分析的預測準確性。

臨床核准流程變得越來越漫長。

人工智慧篩檢工具的臨床核准流程漫長而複雜，延緩了商業化進程。企業被迫在合規和監管申請方面投入巨資。與擁有成熟監管經驗的大型競爭對手相比，中小企業尤其脆弱。各國政府優先考慮病人安全，這進一步延緩了核准進程。在獲得監管部門批准之前，消費者難以獲得這些創新工具。核准速度緩慢降低了快速創新的獎勵。除非縮短核准週期，否則冗長的核准流程將持續構成挑戰。

新型冠狀病毒（COVID-19）的影響：

疫情擾亂了臨床試驗，延緩了生物標記的檢驗。封鎖措施減緩了研究活動，並降低了新型篩檢工具的短期應用。另一方面，這場危機凸顯了遠距醫療和人工智慧醫療解決方案的重要性。世界各國政府在其復甦計畫中優先考慮數位醫療，並加強了人工智慧篩檢的角色。企業重新聚焦於擴充性和適應性強的技術，以確保醫療服務的連續性。這場危機也提高了家庭對神經系統健康需求的認知。

在預測期內，影像生物標記細分市場預計將佔據最大的市場佔有率。

預計在預測期內，影像生物標記領域將佔據最大的市場佔有率，因為它能夠提供關於大腦結構和功能的詳細資訊。各公司正在利用影像生物標記來支持早期診斷和介入。各國政府正在將影像研究作為其神經發育工作的重要組成部分。家庭正受益於篩檢結果準確性和可靠性的提高。人工智慧驅動的影像分析技術的進步正在提升擴充性和預測能力。官民合作關係正在加速其在臨床實踐中的應用。

預計人工智慧（AI）領域在預測期內將呈現最高的複合年成長率。

在預測期內，人工智慧 (AI) 領域預計將呈現最高的成長率，這主要得益於對預測分析和自適應篩檢解決方案日益成長的需求。企業正在部署人工智慧平台，以提高診斷的準確性和效率。各國政府也支持醫療保健系統採用人工智慧技術。家庭用戶對既便利又先進的篩檢工具的需求不斷成長。機器學習和深度學習的進步正在提升預測能力。中小企業正在神經發育領域的細分人工智慧應用中找到商機。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其強大的醫療保健基礎設施和對人工智慧技術的早期應用。美國在醫院和研究機構部署基於人工智慧的篩檢工具方面發揮著主導作用。各公司正大力投資先進演算法和生物標記研究。與其他地區相比，北美家庭對值得信賴且易於使用的篩檢解決方案的需求更高。法律規範在支持創新的同時，也確保了合規性。政府正在資助神經發育篩檢的先導計畫。這些因素共同鞏固了北美的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於快速的數位化進程和不斷擴大的醫療保健投資。中國、印度和日本等國家正在擴大人工智慧醫療保健項目，以滿足日益成長的神經系統健康需求。不斷壯大的中產階級正在推動便捷篩檢解決方案的需求。各國政府正在實施扶持措施，以促進人工智慧醫療保健領域的本土創新。當地企業正在擴大生產規模，以滿足國內外需求。血液衍生生物標記和人工智慧分析技術的進步正在加速該地區的應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球神經認知生物標記解決方案市場：按生物標記類型分類

  • 影像生物標記
  • 電生理生物標記
  • 數位生物標記
  • 分子生物標記
  • 其他

第6章 全球神經認知生物標記解決方案市場：依技術分類

  • 人工智慧（AI）
  • 神經影像學
  • 腦電圖（EEG）
  • 驗血
  • 其他

第7章 全球神經認知生物標記解決方案市場：按適應症分類

  • 神經退化性疾病
  • 神經發育障礙
  • 創傷性腦損傷
  • 精神疾病
  • 其他

第8章 全球神經認知生物標記解決方案市場：按樣本類型分類

  • 血
  • 腦脊髓液
  • 腦部影像數據
  • 數位生理數據
  • 其他

第9章 全球神經認知生物標記解決方案市場：按最終用戶分類

  • 醫院
  • 診斷檢查室
  • 研究機構
  • 製藥公司
  • 其他

第10章 全球神經認知生物標記解決方案市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Roche Holding AG
  • QUIBIM SL
  • C2N Diagnostics LLC
  • Biogen Inc.
  • Philips Healthcare
  • Siemens Healthineers AG
  • GE HealthCare Technologies Inc.
  • FUJIFILM Holdings Corporation
  • Canon Medical Systems Corporation
  • Natus Medical Incorporated
  • Compumedics Limited
  • Neuroelectrics SL
  • EMOTIV Inc.
  • BrainScope Company, Inc.
  • Quest Diagnostics Incorporated
Product Code: SMRC38805

According to Stratistics MRC, the Global Neurocognitive Biomarker Solutions Market is accounted for $5.2 billion in 2026 and is expected to reach $19.8 billion by 2034 growing at a CAGR of 18.2% during the forecast period. Neurocognitive biomarker solutions are advanced technologies that identify, measure, and analyze biological and digital indicators associated with cognitive function, neurological disorders, and brain health. These solutions combine neuroimaging, blood-based biomarkers, electrophysiological measurements, wearable sensors, artificial intelligence, and digital cognitive assessments to support early diagnosis, disease monitoring, treatment selection, and personalized care. Neurocognitive biomarker solutions are widely used in clinical research, hospitals, pharmaceutical development, and precision medicine. Growing prevalence of neurological disorders and increasing investment in biomarker-based diagnostics are driving the global adoption of neurocognitive biomarker solutions.

Market Dynamics:

Driver:

Rising neurological disease prevalence

Global prevalence of neurological disorders such as autism spectrum conditions, ADHD, and developmental delays is steadily increasing. This trend is fueling demand for AI-driven screening tools that enable earlier detection and intervention. Enterprises are investing in advanced algorithms to improve diagnostic accuracy and reduce reliance on traditional methods. Governments are supporting neurodevelopment initiatives through healthcare funding and policy frameworks. Families and caregivers increasingly seek accessible, non-invasive screening methods for children and adults. Advances in machine learning and multimodal data integration enhance predictive capabilities. Collectively, these factors ensure strong momentum for AI-based neurodevelopment screening adoption.

Restraint:

Complex biomarker validation processes

Validation of biomarkers requires extensive clinical trials and regulatory approvals, which slows down commercialization. Enterprises face high costs and long timelines in developing clinically reliable biomarkers. Smaller firms struggle to manage validation compared to larger competitors with advanced research capacity. Regulatory frameworks demand rigorous evidence before approval, adding complexity. Consumer trust in AI-based screening depends on validated biomarkers that demonstrate accuracy. The need for standardized protocols across regions further complicates adoption. As a result, biomarker validation remains a significant barrier to rapid market growth.

Opportunity:

Blood-based biomarker innovations

Blood-based biomarkers offer a promising pathway for non-invasive neurodevelopment screening. Innovations in this area present opportunities to expand AI-based diagnostics beyond imaging. Enterprises benefit from improved accessibility and reduced reliance on costly neuroimaging techniques. Governments are encouraging biomarker research as part of precision medicine strategies. Families increasingly demand simple and reliable screening methods, accelerating investment in blood-based solutions. Advances in AI integration enhance the predictive power of biomarker analysis.

Threat:

Lengthy clinical approval timelines

Clinical approval processes for AI-based screening tools are lengthy and complex, delaying commercialization. Enterprises must invest heavily in compliance and regulatory submissions. Smaller firms are particularly vulnerable compared to larger competitors with established regulatory expertise. Governments emphasize patient safety, which adds further delays to approvals. Consumers face limited access to innovative tools until regulatory clearance is achieved. The slow pace of approvals reduces incentives for rapid innovation. Unless timelines are streamlined, lengthy approval processes will remain a challenge.

Covid-19 Impact:

The pandemic disrupted clinical trials and slowed down biomarker validation efforts. Lockdowns delayed research activities and reduced short-term adoption of new screening tools. At the same time, the crisis highlighted the importance of remote and AI-driven healthcare solutions. Governments emphasized digital health in recovery plans, reinforcing the role of AI-based screening. Enterprises renewed focus on scalable and adaptive technologies to ensure continuity of care. Families became more aware of neurological health needs during the crisis.

The imaging biomarkers segment is expected to be the largest during the forecast period

The imaging biomarkers segment is expected to account for the largest market share during the forecast period as these tools provide detailed insights into brain structure and function. Enterprises rely on imaging biomarkers to support early diagnosis and intervention. Governments are prioritizing imaging research as part of neurodevelopment initiatives. Families benefit from improved accuracy and reliability in screening outcomes. Advances in AI-driven image analysis enhance scalability and predictive power. Public-private partnerships are accelerating deployment in clinical settings.

The artificial intelligence segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the artificial intelligence segment is predicted to witness the highest growth rate due to rising demand for predictive analytics and adaptive screening solutions. Enterprises are adopting AI-driven platforms to improve diagnostic accuracy and efficiency. Governments are supporting AI integration in healthcare frameworks. Families increasingly demand accessible and intelligent screening tools. Advances in machine learning and deep learning enhance predictive capabilities. Smaller firms find opportunities in niche AI applications within neurodevelopment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong healthcare infrastructure and early adoption of AI technologies. The U.S. leads in deploying AI-based screening tools across hospitals and research institutions. Enterprises are investing heavily in advanced algorithms and biomarker research. Families demand reliable and accessible screening solutions at higher rates compared to other regions. Regulatory frameworks support innovation while ensuring compliance. Governments are funding pilot projects for neurodevelopment screening. These factors collectively secure North America's leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid digitalization and expanding healthcare investments. Countries such as China, India, and Japan are scaling up AI-based healthcare projects to meet rising neurological health needs. Growing middle-class populations are fueling demand for accessible screening solutions. Governments are introducing supportive policies to encourage domestic innovation in AI healthcare. Local companies are expanding production to meet both domestic and export requirements. Advances in blood-based biomarkers and AI-driven analytics accelerate adoption in this region.

Key players in the market

Some of the key players in Neurocognitive Biomarker Solutions Market include Roche Holding AG, QUIBIM S.L., C2N Diagnostics LLC, Biogen Inc., Philips Healthcare, Siemens Healthineers AG, GE HealthCare Technologies Inc., FUJIFILM Holdings Corporation, Canon Medical Systems Corporation, Natus Medical Incorporated, Compumedics Limited, Neuroelectrics S.L., EMOTIV Inc., BrainScope Company, Inc. and Quest Diagnostics Incorporated.

Key Developments:

In June 2026, C2N Diagnostics LLC partnered with SouthGenetics to commercialize its PrecivityAD2 blood test across international markets. The high-resolution mass spectrometry assay detects plasma p-tau217 and amyloid ratios to accurately identify early Alzheimer's pathology.

In February 2026, Biogen Inc. integrated a portfolio of novel digital and fluid biomarker assays into its late-stage neurodegeneration trials. The multi-modal monitoring framework tracks target engagement and cognitive stabilization in patients receiving disease-modifying therapies.

Biomarker Types Covered:

  • Imaging Biomarkers
  • Electrophysiological Biomarkers
  • Digital Biomarkers
  • Molecular Biomarkers
  • Other Biomarker Types

Technologies Covered:

  • Artificial Intelligence
  • Neuroimaging
  • Electroencephalography (EEG)
  • Blood-Based Analysis
  • Other Technologies

Clinical Indications Covered:

  • Neurodegenerative Disorders
  • Neurodevelopmental Disorders
  • Traumatic Brain Injury
  • Psychiatric Disorders
  • Other Clinical Indications

Sample Types Covered:

  • Blood
  • Cerebrospinal Fluid
  • Brain Imaging Data
  • Digital Physiological Data
  • Other Sample Types

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Neurocognitive Biomarker Solutions Market, By Biomarker Type

  • 5.1 Imaging Biomarkers
  • 5.2 Electrophysiological Biomarkers
  • 5.3 Digital Biomarkers
  • 5.4 Molecular Biomarkers
  • 5.5 Other Biomarker Types

6 Global Neurocognitive Biomarker Solutions Market, By Technology

  • 6.1 Artificial Intelligence
  • 6.2 Neuroimaging
  • 6.3 Electroencephalography (EEG)
  • 6.4 Blood-Based Analysis
  • 6.5 Other Technologies

7 Global Neurocognitive Biomarker Solutions Market, By Clinical Indication

  • 7.1 Neurodegenerative Disorders
  • 7.2 Neurodevelopmental Disorders
  • 7.3 Traumatic Brain Injury
  • 7.4 Psychiatric Disorders
  • 7.5 Other Clinical Indications

8 Global Neurocognitive Biomarker Solutions Market, By Sample Type

  • 8.1 Blood
  • 8.2 Cerebrospinal Fluid
  • 8.3 Brain Imaging Data
  • 8.4 Digital Physiological Data
  • 8.5 Other Sample Types

9 Global Neurocognitive Biomarker Solutions Market, By End User

  • 9.1 Hospitals
  • 9.2 Diagnostic Laboratories
  • 9.3 Research Institutes
  • 9.4 Pharmaceutical Companies
  • 9.5 Other End Users

10 Global Neurocognitive Biomarker Solutions Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Roche Holding AG
  • 13.2 QUIBIM S.L.
  • 13.3 C2N Diagnostics LLC
  • 13.4 Biogen Inc.
  • 13.5 Philips Healthcare
  • 13.6 Siemens Healthineers AG
  • 13.7 GE HealthCare Technologies Inc.
  • 13.8 FUJIFILM Holdings Corporation
  • 13.9 Canon Medical Systems Corporation
  • 13.10 Natus Medical Incorporated
  • 13.11 Compumedics Limited
  • 13.12 Neuroelectrics S.L.
  • 13.13 EMOTIV Inc.
  • 13.14 BrainScope Company, Inc.
  • 13.15 Quest Diagnostics Incorporated

List of Tables

  • Table 1 Global Neurocognitive Biomarker Solutions Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neurocognitive Biomarker Solutions Market, By Biomarker Type (2023-2034) ($MN)
  • Table 3 Global Neurocognitive Biomarker Solutions Market, By Imaging Biomarkers (2023-2034) ($MN)
  • Table 4 Global Neurocognitive Biomarker Solutions Market, By Electrophysiological Biomarkers (2023-2034) ($MN)
  • Table 5 Global Neurocognitive Biomarker Solutions Market, By Digital Biomarkers (2023-2034) ($MN)
  • Table 6 Global Neurocognitive Biomarker Solutions Market, By Molecular Biomarkers (2023-2034) ($MN)
  • Table 7 Global Neurocognitive Biomarker Solutions Market, By Other Biomarker Types (2023-2034) ($MN)
  • Table 8 Global Neurocognitive Biomarker Solutions Market, By Technology (2023-2034) ($MN)
  • Table 9 Global Neurocognitive Biomarker Solutions Market, By Artificial Intelligence (2023-2034) ($MN)
  • Table 10 Global Neurocognitive Biomarker Solutions Market, By Neuroimaging (2023-2034) ($MN)
  • Table 11 Global Neurocognitive Biomarker Solutions Market, By Electroencephalography (EEG) (2023-2034) ($MN)
  • Table 12 Global Neurocognitive Biomarker Solutions Market, By Blood-Based Analysis (2023-2034) ($MN)
  • Table 13 Global Neurocognitive Biomarker Solutions Market, By Other Technologies (2023-2034) ($MN)
  • Table 14 Global Neurocognitive Biomarker Solutions Market, By Clinical Indication (2023-2034) ($MN)
  • Table 15 Global Neurocognitive Biomarker Solutions Market, By Neurodegenerative Disorders (2023-2034) ($MN)
  • Table 16 Global Neurocognitive Biomarker Solutions Market, By Neurodevelopmental Disorders (2023-2034) ($MN)
  • Table 17 Global Neurocognitive Biomarker Solutions Market, By Traumatic Brain Injury (2023-2034) ($MN)
  • Table 18 Global Neurocognitive Biomarker Solutions Market, By Psychiatric Disorders (2023-2034) ($MN)
  • Table 19 Global Neurocognitive Biomarker Solutions Market, By Other Clinical Indications (2023-2034) ($MN)
  • Table 20 Global Neurocognitive Biomarker Solutions Market, By Sample Type (2023-2034) ($MN)
  • Table 21 Global Neurocognitive Biomarker Solutions Market, By Blood (2023-2034) ($MN)
  • Table 22 Global Neurocognitive Biomarker Solutions Market, By Cerebrospinal Fluid (2023-2034) ($MN)
  • Table 23 Global Neurocognitive Biomarker Solutions Market, By Brain Imaging Data (2023-2034) ($MN)
  • Table 24 Global Neurocognitive Biomarker Solutions Market, By Digital Physiological Data (2023-2034) ($MN)
  • Table 25 Global Neurocognitive Biomarker Solutions Market, By Other Sample Types (2023-2034) ($MN)
  • Table 26 Global Neurocognitive Biomarker Solutions Market, By End User (2023-2034) ($MN)
  • Table 27 Global Neurocognitive Biomarker Solutions Market, By Hospitals (2023-2034) ($MN)
  • Table 28 Global Neurocognitive Biomarker Solutions Market, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 29 Global Neurocognitive Biomarker Solutions Market, By Research Institutes (2023-2034) ($MN)
  • Table 30 Global Neurocognitive Biomarker Solutions Market, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 31 Global Neurocognitive Biomarker Solutions Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.